The University of Sydney
Stories naming Professor Michael Valenzuela. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.
Weekly roundup of four raises: Guzman y Gomez banked $134.5 million at a $1.73 billion valuation, Honey Insurance sealed a $108 million Series A, Skin2Neuron gathered $4 million, and AVESS Energy took $1 million.
Also SmartCompany
Sydney biotech Skin2Neuron raised $4 million from SYNthesis BioVentures to develop a hair-follicle cell therapy for Alzheimer's, while the investor reached the first $20 million close of its $75 million bioscience fund.
Also SmartCompany